BOSTON, March 12 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, has appointed Jacque Fisher as a Vice President and General Manager in the Company's Medical Communications Services business. Ms. Fisher brings more than 20 years of experience in biopharmaceutical industry marketing to PAREXEL. In this position, Ms. Fisher leads a global team of experts who assist clients in translating complex scientific information into integrated communications. She also has responsibility for overall client management and advising biopharmaceutical companies on the effectiveness of their medical communications programs.
"Today's highly regulated marketplace demands unique expertise. Clients increasingly turn to our medical communications team for an evidence-based approach to educate physicians and patients about key points of difference for products and to build a strong knowledge base among key opinion leaders," said Glenn Van Deusen, Corporate Vice President and Worldwide Head of Medical Communications Services, PAREXEL. "We expect our clients to greatly benefit from Ms. Fisher's expertise in providing strategic medical communications programs and in-depth experience with quality standards and regulatory requirements. Her leadership will help PAREXEL continue to meet the evolving medical communications needs of our clients."
"Biopharmaceutical companies must begin strategic planning and execution of medical communications in early phases of clinical development to achieve the greatest market awareness and education about their products," said Ms. Jacque Fisher. "I am pleased to join PAREXEL and work with such a high caliber team of medical communications experts to help clients create customized, powerful, ongoing communications from Phase II through post-launch."
Prior to joining PAREXEL, Ms. Fisher was President of Gardiner-Caldwell U.S., a former business unit of Thomson Healthcare. Before leading the U.S. business unit, she was a Business Unit Manager within Thomson Healthcare's medical communications group based in the U.K. Previously, Ms. Fisher held senior-level positions at Page & Moy Marketing in the U.K. She has extensive experience working on a variety of medical education and communications programs, involving content development and message delivery, for large, mid- size, and small and emerging biopharmaceutical companies, across a broad range of therapeutic areas, including oncology, neurology, HIV, psychiatry and dermatology. Ms. Fisher holds a Bachelor's degree from University College London.
PAREXEL's Medical Communications Services provides integrated medical communications that help accelerate product adoption and professional recommendations. Services include medical writing, publication planning, meetings and exhibits, key opinion leader (KOL) development, e-communications, clinical communications, competitive insights, market and patient access, and reimbursement services.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has more than 7,300 employees. For more information about PAREXEL International visit http://www.PAREXEL.com .
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation,
and Perceptive Informatics is a trademark of Perceptive Informatics, Inc.
All other names or marks may be registered trademarks or trademarks of
their respective business and are hereby acknowledged.
Jennifer Baird, Director of Public Relations Rebecca Passo
PAREXEL International SHIFT Communications
Tel: +781-434-4409 Tel : +617-779-1817
|SOURCE PAREXEL International Corporation|
Copyright©2008 PR Newswire.
All rights reserved